Dosage forms

OneLavi.com Now Offers NanoVeda’s Rapid Dissolve Oral Strips to America

Retrieved on: 
Wednesday, June 30, 2021
Dosage forms, Thin-film drug delivery, Health sciences, Ayurveda, Medicine, Health care

NanoVeda announced this week that OneLavi.com will carry its fast-dissolving oral strips, which provide superior body absorption with great taste for your daily dietary nutrition.

Key Points: 
  • NanoVeda announced this week that OneLavi.com will carry its fast-dissolving oral strips, which provide superior body absorption with great taste for your daily dietary nutrition.
  • We are excited that OneLavi.com has chosen our 21st-century nutritional products, said Rakshit Mehta, founder of the Swiss-based NanoVeda health and wellness company.
  • NanoVedas rapid dissolving strips combine 1,000 years of Ayurveda alternative medicine with modern Swiss innovation.
  • Mehta points out that NanoVedas strips are lightweight and convenient to take with you wherever you go.

Oyster Point Pharma Provides Key Supply Chain Insight For OC-01 (varenicline) Nasal Spray

Retrieved on: 
Tuesday, June 29, 2021
Medicine, Health sciences, Clinical medicine, Smoking cessation, Nicotinic agonists, Benzazepines, Varenicline, Nose, Dosage forms, Nasal spray, Mace

Oyster Point Pharma has not observed any measurable impurities in its OC-01 (varenicline) nasal spray.

Key Points: 
  • Oyster Point Pharma has not observed any measurable impurities in its OC-01 (varenicline) nasal spray.
  • Oyster Point Pharma is developing OC-01 (varenicline) nasal spray to treat the signs and symptoms of dry eye disease.
  • Oyster Point Pharma currently sources OC-01 (varenicline) nasal spray active pharmaceutical ingredient (API), varenicline tartrate, from a supplier unrelated to the manufacturer that has suspended distribution due to nitrosamine being above acceptable levels.
  • OC-01 (varenicline) nasal spray is an investigational new drug and has not been approved for any use in any country.

EpiFaith® Expanding to U.S. Military Hospitals After a Newly Awarded Agreement by the Defense Logistics Agency

Retrieved on: 
Tuesday, June 29, 2021
Research, General Health, Other Defense, Contracts, Hardware, Consumer, Technology, Defense, Science, Engineering, Women, Health, Manufacturing, Medicine, Medical specialties, Clinical medicine, Dosage forms, Childbirth, Epidural administration, Regional anesthesia, Drug paraphernalia, Zimmer Biomet Robotics, Syringe, Anesthesia, Medtech

Flat Medical Co., Ltd., a MedTech company specializing in safety solutions for anesthesia and critical care procedures, has announced that it has been awarded a Distribution and Pricing Agreement (DAPA) by the Defense Logistics Agency for its flagship product EpiFaith.

Key Points: 
  • Flat Medical Co., Ltd., a MedTech company specializing in safety solutions for anesthesia and critical care procedures, has announced that it has been awarded a Distribution and Pricing Agreement (DAPA) by the Defense Logistics Agency for its flagship product EpiFaith.
  • EpiFaith will soon be available in all U.S. military hospitals across the globe.
  • We found using the EpiFaith syringe was often better than using their regular loss-of-resistance syringe, he added.
  • Finally, we can help deliver innovative solutions and perform safe epidural practices with respected physicians in military hospitals together through this agreement, said Dr. Joseph Luo, CEO of Flat Medical.

Walmart.com Now Offers OnMi Transdermal Supplement Patches

Retrieved on: 
Monday, June 28, 2021
Health sciences, Pharmacology, Dosage forms, Pharmaceutical sciences, Pharmaceutical industry, Routes of administration, Transdermal patch, Tablet, Capsule, Crave

PALM BEACH, FL, June 28, 2021 (GLOBE NEWSWIRE) -- Walmart.com now offers OnMi patches for wellness, support, and relief.

Key Points: 
  • PALM BEACH, FL, June 28, 2021 (GLOBE NEWSWIRE) -- Walmart.com now offers OnMi patches for wellness, support, and relief.
  • OnMi transdermal patches stand apart from other supplements on the market because it gives you 100 percent vitamins and minerals without any filler ingredients or sugar.
  • For 40 percent of consumers in the United States who have trouble swallowing pills, tablets or capsules, OnMi patches are a solution they will love.
  • OnMi also offers Crave-Less, which helps you say no to cravings, and Hangover, which boosts yourbody's ability to bounce back.

Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany

Retrieved on: 
Monday, June 28, 2021
Medicine, Clinical medicine, Medical specialties, Nose, Allergology, Dosage forms, Human nose, Allergen, Nasal spray

Bentrio (AM-301) is a drug-free nasal spray for personal protection against airborne viruses and allergens.

Key Points: 
  • Bentrio (AM-301) is a drug-free nasal spray for personal protection against airborne viruses and allergens.
  • Upon application into the nose, Bentrio forms a protective gel layer on the nasal mucosa.
  • Auris Medical is dedicated to developing therapeutics that address important unmet medical needs.
  • The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol EARS.

Global Digital Dose Inhalers Market to Reach $4.9 Billion by 2026

Retrieved on: 
Friday, June 25, 2021
Health sciences, Asthma, Dosage forms, Health care, Inhaler, Respiratory therapy, Health

SAN FRANCISCO, June 25, 2021 /PRNewswire/ --A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Digital Dose Inhalers - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, June 25, 2021 /PRNewswire/ --A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Digital Dose Inhalers - Global Market Trajectory & Analytics" .
  • Amid the COVID-19 crisis, the global market for Digital Dose Inhalers estimated at US$2.3 Billion in the year 2020, is projected to reach a revised size of US$4.9 Billion by 2026, growing at a CAGR of 13.1% over the analysis period.
  • This segment currently accounts for a 35.7% share of the global Digital Dose Inhalers market.
  • The U.S. Market is Estimated at $1.1 Billion in 2021, While China is Forecast to Reach $418.2 Million by 2026
    The Digital Dose Inhalers market in the U.S. is estimated at US$1.1 Million in the year 2021.

Worldwide Keloid Treatment Industry to 2026 - Growing Awareness Among People Regarding the Availability of Treatment Options Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 24, 2021
Health, General Health, Health sciences, Pharmacology, Health, Dosage forms, Corticosteroids, Keloid, Topical medication, Silicone, Gel, Scar

The global keloid treatment market is expected to grow due to the rapid development made by the technologically upgraded skincare products.

Key Points: 
  • The global keloid treatment market is expected to grow due to the rapid development made by the technologically upgraded skincare products.
  • Also, growing awareness amongst the people regarding the availability of treatment options and other products available to cure keloid is a key factor in helping the keloid treatment market growth.
  • Based on product type, the global keloid treatment market is segmented into Elastic Wraps, Sprays, Ointment, Creams, Oils, Topical Gels & Gel Sheets.
  • Based on treatment, the global keloid treatment market is segmented into ligature, radiation therapy, surgical treatment, laser treatment, steroid injections, corticosteroid injections (intralesional steroids), Silicone gel or sheeting, interferon.

Advisory - One lot of Linessa 21 birth control pills recalled due to missing and mispackaged pills

Retrieved on: 
Sunday, June 20, 2021
Health sciences, Pharmacology, Health care, Packaging, Pharmaceutical industry, Dosage forms, Blister pack, Combined oral contraceptive pill, Pharmacare, Tablet, Pill

Issue:Aspen Pharmacare Canada Inc. is recalling one lot due to missing and mispackaged pills.

Key Points: 
  • Issue:Aspen Pharmacare Canada Inc. is recalling one lot due to missing and mispackaged pills.
  • What to do: If you have a package with missing or mispackaged pills, return it to your pharmacy for a replacement package.
  • Aspen Pharmacare Canada Inc. is recalling one lot (lot 200049, expiry 03/2023) of Linessa 21, a prescription birth control pill, due to missing and mispackaged pills.
  • Some blister packs may be missing pills, may contain more than one tablet in a blister pocket, and may contain pills in the wrong order.

FDA Approves a Nasal Antihistamine for Nonprescription Use

Retrieved on: 
Thursday, June 17, 2021
Medicine, Medical specialties, Clinical medicine, Allergology, Chloroarenes, Dosage forms, Azelastine, Lactams, Nasal spray, Rhinitis, Food and Drug Administration, Bayer

SILVER SPRING, Md., June 17, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration today approved a nasal antihistamine for nonprescription use through a process called a partial prescription to nonprescription switch.

Key Points: 
  • SILVER SPRING, Md., June 17, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration today approved a nasal antihistamine for nonprescription use through a process called a partial prescription to nonprescription switch.
  • The FDA approved Astepro (azelastine hydrochloride nasal spray, 0.15%) for seasonal and perennial allergic rhinitiscommonly known as allergiesfor adults and children six years of age and older.
  • "Today's approval provides individuals an option for a safe and effective nasal antihistamine without requiring the assistance of a healthcare provider."
  • The FDA granted the approval of nonprescription Astepro to Bayer Healthcare LLC.

MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Application Acceptance From The FDA

Retrieved on: 
Wednesday, June 16, 2021
Health sciences, Health care, Health, MannKind Corporation, Thousand Oaks, California, Dosage forms, Asthma, United Therapeutics, Inhaler, DPI, Doctor of Pharmacy

MannKind and United Therapeutics are also developing BluHale, a Bluetooth-connected accessory for the Tyvaso DPI inhaler with a companion mobile application intended to help patients track information about their inhaler use.

Key Points: 
  • MannKind and United Therapeutics are also developing BluHale, a Bluetooth-connected accessory for the Tyvaso DPI inhaler with a companion mobile application intended to help patients track information about their inhaler use.
  • "We are energized by the acceptance of the Tyvaso DPI NDA for priority review," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation.
  • "MannKind is driven to deliver therapeutics in ways that can help improve patient lives for the better.
  • MannKind and United Therapeutics entered into a worldwide exclusive licensing and collaboration agreement in September 2018 for the development and commercialization of Tyvaso DPI.